Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6509
    -0.0027 (-0.41%)
     
  • OIL

    82.41
    +1.06 (+1.30%)
     
  • GOLD

    2,232.00
    +19.30 (+0.87%)
     
  • Bitcoin AUD

    108,820.08
    -1,033.71 (-0.94%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6020
    -0.0011 (-0.18%)
     
  • AUD/NZD

    1.0892
    +0.0012 (+0.11%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,251.54
    -29.30 (-0.16%)
     
  • FTSE

    7,956.16
    +24.18 (+0.30%)
     
  • Dow Jones

    39,825.88
    +65.80 (+0.17%)
     
  • DAX

    18,490.26
    +13.17 (+0.07%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics

Exelixis (EXEL) reported $423.92 million in revenue for the quarter ended December 2022, representing a year-over-year decline of 6%. EPS of -$0.03 for the same period compares to $0.29 a year ago.

The reported revenue represents a surprise of +1.82% over the Zacks Consensus Estimate of $416.33 million. With the consensus EPS estimate being -$0.05, the EPS surprise was +40.00%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Exelixis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Collaboration services revenues: $8.42 million versus $45.04 million estimated by 12 analysts on average.

  • Revenues- Net product: $377.42 million versus $376.43 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +24.7% change.

  • Revenues- Net product -Cabometyx: $372.60 million versus the five-analyst average estimate of $368.13 million. The reported number represents a year-over-year change of +26.3%.

  • Revenues- Net product -Cometriq: $4.90 million versus the five-analyst average estimate of $7.03 million. The reported number represents a year-over-year change of -35.5%.

  • Revenues- License: $38.08 million versus the three-analyst average estimate of $35.09 million. The reported number represents a year-over-year change of -71.4%.

View all Key Company Metrics for Exelixis here>>>

Shares of Exelixis have returned +2.5% over the past month versus the Zacks S&P 500 composite's +5.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research